BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 29554366)

  • 1. ZYH005, a novel DNA intercalator, overcomes all-trans retinoic acid resistance in acute promyelocytic leukemia.
    Tong Q; You H; Chen X; Wang K; Sun W; Pei Y; Zhao X; Yuan M; Zhu H; Luo Z; Zhang Y
    Nucleic Acids Res; 2018 Apr; 46(7):3284-3297. PubMed ID: 29554366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CUDC-101 overcomes arsenic trioxide resistance via caspase-dependent promyelocytic leukemia-retinoic acid receptor alpha degradation in acute promyelocytic leukemia.
    Zhang T; Ma D; Wei D; Lu T; Yu K; Zhang Z; Wang W; Fang Q; Wang J
    Anticancer Drugs; 2020 Feb; 31(2):158-168. PubMed ID: 31584454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia.
    Marasca R; Zucchini P; Galimberti S; Leonardi G; Vaccari P; Donelli A; Luppi M; Petrini M; Torelli G
    Haematologica; 1999 Nov; 84(11):963-8. PubMed ID: 10553155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia.
    Coltella N; Valsecchi R; Ponente M; Ponzoni M; Bernardi R
    Clin Cancer Res; 2015 Aug; 21(16):3685-94. PubMed ID: 25931453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LG-362B targets PML-RARα and blocks ATRA resistance of acute promyelocytic leukemia.
    Wang X; Lin Q; Lv F; Liu N; Xu Y; Liu M; Chen Y; Yi Z
    Leukemia; 2016 Jul; 30(7):1465-74. PubMed ID: 27012866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The molecular biology of acute promyelocytic leukemia.
    Slack JL; Gallagher RE
    Cancer Treat Res; 1999; 99():75-124. PubMed ID: 9891864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primaquine phosphate induces the apoptosis of ATRA-resistant acute promyelocytic leukemia cells by inhibition of the NF-κB pathway.
    Ma L; Chen L; Li H; Ge L; Wang S; Zhang Z; Huang H; Shi L; Li T; Gu H; Lyu J; He L
    J Leukoc Biol; 2020 Apr; 107(4):685-693. PubMed ID: 32125014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse.
    Iaccarino L; Ottone T; Alfonso V; Cicconi L; Divona M; Lavorgna S; Travaglini S; Ferrantini A; Falconi G; Baer C; Usai M; Forghieri F; Venditti A; Del Principe MI; Arcese W; Voso MT; Haferlach T; Lo-Coco F
    Am J Hematol; 2019 Oct; 94(10):1091-1097. PubMed ID: 31292998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigallocatechin-3-gallate promotes all-trans retinoic acid-induced maturation of acute promyelocytic leukemia cells via PTEN.
    Yao S; Zhong L; Chen M; Zhao Y; Li L; Liu L; Xu T; Xiao C; Gan L; Shan Z; Liu B
    Int J Oncol; 2017 Sep; 51(3):899-906. PubMed ID: 28766684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells.
    Zheng X; Seshire A; Rüster B; Bug G; Beissert T; Puccetti E; Hoelzer D; Henschler R; Ruthardt M
    Haematologica; 2007 Mar; 92(3):323-31. PubMed ID: 17339181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NLS-RARα Inhibits the Effects of All-trans Retinoic Acid on NB4 Cells by Interacting with P38α MAPK.
    Xiao C; Zhong L; Shan Z; Xu T; Gan L; Song H; Yang R; Li L; Liu B
    Int J Med Sci; 2016; 13(8):611-9. PubMed ID: 27499693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Common defects of different retinoic acid resistant promyelocytic leukemia cells are persistent telomerase activity and nuclear body disorganization.
    Nason-Burchenal K; Maerz W; Albanell J; Allopenna J; Martin P; Moore MA; Dmitrovsky E
    Differentiation; 1997 Aug; 61(5):321-31. PubMed ID: 9342843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Basic and clinical studies of the gene product-targeting therapy based on leukemogenesis--editorial].
    Chen SJ; Chen LJ; Zhou GB
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb; 13(1):1-8. PubMed ID: 15748426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PML/RARα-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia.
    Bräuer-Hartmann D; Hartmann JU; Wurm AA; Gerloff D; Katzerke C; Verga Falzacappa MV; Pelicci PG; Müller-Tidow C; Tenen DG; Niederwieser D; Behre G
    Cancer Res; 2015 Aug; 75(16):3411-24. PubMed ID: 26041820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of all-trans retinoic acid and arsenic trioxide on tissue factor expression of acute promyelocytic leukemia cells].
    Guo W; Wang H; Zhao W
    Zhonghua Yi Xue Za Zhi; 2000 May; 80(5):327-31. PubMed ID: 11798779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia.
    Lehmann-Che J; Bally C; Letouzé E; Berthier C; Yuan H; Jollivet F; Ades L; Cassinat B; Hirsch P; Pigneux A; Mozziconacci MJ; Kogan S; Fenaux P; de Thé H
    Nat Commun; 2018 May; 9(1):2047. PubMed ID: 29795382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells.
    Chen GQ; Shi XG; Tang W; Xiong SM; Zhu J; Cai X; Han ZG; Ni JH; Shi GY; Jia PM; Liu MM; He KL; Niu C; Ma J; Zhang P; Zhang TD; Paul P; Naoe T; Kitamura K; Miller W; Waxman S; Wang ZY; de The H; Chen SJ; Chen Z
    Blood; 1997 May; 89(9):3345-53. PubMed ID: 9129041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Designed ATRA analogue active against ATRA-resistant acute promyelocytic leukemia cells having a single nucleotide substitution in their retinoic acid receptor.
    Komura N; Ikeda Y; Masuda N; Umezawa Y; Ito K; Kizaki M; Umezawa K
    Leuk Res; 2007 Mar; 31(3):301-13. PubMed ID: 16968653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
    Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H
    Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RXRα ligand Z-10 induces PML-RARα cleavage and APL cell apoptosis through disrupting PML-RARα/RXRα complex in a cAMP-independent manner.
    Xu L; Zeng Z; Zhang W; Ren G; Ling X; Huang F; Xie P; Su Y; Zhang XK; Zhou H
    Oncotarget; 2017 Feb; 8(7):12311-12322. PubMed ID: 28129653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.